- Home
- MRUS vs SLG Comparison
MRUS vs SLG Comparison
Compare MRUS & SLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- SLG
- Stock Information
- Founded
- MRUS 2003
- SLG 1980
- Country
- MRUS Netherlands
- SLG United States
- Employees
- MRUS N/A
- SLG N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- SLG Real Estate Investment Trusts
- Sector
- MRUS Health Care
- SLG Real Estate
- Exchange
- MRUS Nasdaq
- SLG Nasdaq
- Market Cap
- MRUS 4.1B
- SLG 4.6B
- IPO Year
- MRUS 2016
- SLG 1997
- Fundamental
- Price
- MRUS $52.90
- SLG $61.43
- Analyst Decision
- MRUS Strong Buy
- SLG Hold
- Analyst Count
- MRUS 12
- SLG 16
- Target Price
- MRUS $87.92
- SLG $66.50
- AVG Volume (30 Days)
- MRUS 1.2M
- SLG 1.1M
- Earning Date
- MRUS 07-31-2025
- SLG 07-16-2025
- Dividend Yield
- MRUS N/A
- SLG 4.96%
- EPS Growth
- MRUS N/A
- SLG N/A
- EPS
- MRUS N/A
- SLG N/A
- Revenue
- MRUS $54,732,000.00
- SLG $648,551,000.00
- Revenue This Year
- MRUS $75.57
- SLG N/A
- Revenue Next Year
- MRUS $31.84
- SLG $2.45
- P/E Ratio
- MRUS N/A
- SLG N/A
- Revenue Growth
- MRUS 42.77
- SLG N/A
- 52 Week Low
- MRUS $33.19
- SLG $45.15
- 52 Week High
- MRUS $62.98
- SLG $82.81
- Technical
- Relative Strength Index (RSI)
- MRUS 54.86
- SLG 48.06
- Support Level
- MRUS $52.53
- SLG $57.78
- Resistance Level
- MRUS $54.81
- SLG $66.37
- Average True Range (ATR)
- MRUS 1.70
- SLG 1.98
- MACD
- MRUS -0.55
- SLG -0.74
- Stochastic Oscillator
- MRUS 39.04
- SLG 31.27
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.